Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension

This study has been completed.

First Received: August 26, 2005 Last Updated: June 1, 2006 History of Changes

Sponsored by:	Novartis
Information provided by:	Novartis
ClinicalTrials.gov Identifier:	NCT00136851

Purpose

This trial is designed to study the efficacy of an amlodipine besylate/benazepril treatment regimen versus an amlodipine treatment regimen in the treatment of severe hypertension.

Condition	Intervention	Phase
Hypertension	Drug: amlodipine besylate/benazepril hydrochloride	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A 6-Week Multi-Center, Randomized, Double-Blind, Parallel Group Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Benazepril hydrochloride Benazepril Amlodipine Amlodipine besylate Lotrel

U.S. FDA Resources

Further study details as provided by Novartis:

Primary Outcome Measures:

Percentage of subjects achieving blood pressure goal which is defined as < 140/90 mm Hg, or < 130/80 mm Hg in subjects with diabetes after 4 weeks

Secondary Outcome Measures:

Percentage of subjects achieving blood pressure goal, defined as < 140/90 mm Hg, or < 130/80 mm Hg in subjects with diabetes after 6 weeks
Change from baseline in the mean sitting systolic blood pressure after 4 and 6 weeks
Change from baseline in the mean sitting diastolic blood pressure after 4 and 6 weeks
Percentage of subjects with swelling in legs or arms after 4 and 6 weeks

Estimated Enrollment:	268
Study Start Date:	December 2004

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Diagnosis of severe hypertension

Exclusion Criteria:

Diastolic blood pressure (DBP) < 60 mm Hg
Serum potassium < 3.5 or > 5.5 mEq/L in the absence of all potassium supplements
Refractory hypertension defined as systolic blood pressure (SBP) ≥ 180 mmHg and/or DBP ≥ 110 mmHg and unresponsive to triple-drug regimens

Other protocol-defined exclusion criteria may apply.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00136851

Locations

United States, New Jersey
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936

Sponsors and Collaborators

Novartis

Investigators

Study Director:

Novartis Pharmaceuticals

More Information

No publications provided

Study ID Numbers:	CCIB002FUS19
Study First Received:	August 26, 2005
Last Updated:	June 1, 2006
ClinicalTrials.gov Identifier:	NCT00136851 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Novartis:

Hypertension

Study placed in the following topic categories:

Calcium, Dietary
Vasodilator Agents
Benazepril
Vascular Diseases
Angiotensin-Converting Enzyme Inhibitors
Calcium Channel Blockers

Cardiovascular Agents
Antihypertensive Agents
Protease Inhibitors
Amlodipine
Hypertension

Additional relevant MeSH terms:

Vasodilator Agents
Molecular Mechanisms of Pharmacological Action
Vascular Diseases
Calcium Channel Blockers
Enzyme Inhibitors
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

Protease Inhibitors
Amlodipine
Membrane Transport Modulators
Therapeutic Uses
Benazepril
Angiotensin-Converting Enzyme Inhibitors
Cardiovascular Diseases
Hypertension

ClinicalTrials.gov processed this record on September 11, 2009